MANAGED-CARE BUDGET IMPACT OF OMALIZUMAB FOR MODERATE TO SEVERE PERSISTENT ASTHMA

被引：0
|
作者：
Turpcu, A. [1 ]
Leung, G. [2 ]
Yim, Y. M. [2 ]
Sapra, S. [2 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
[2] Genentech Inc, San Francisco, CA 94080 USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73672-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A122 / A122
页数：1
相关论文
共 50 条
  • [1] IMPACT OF OMALIZUMAB ON POOR ASTHMA CONTROL EVENTS AND MEDICATION UTILISATION IN PATIENTS WITH MODERATE OR SEVERE PERSISTENT ASTHMA
    Yu, T. C.
    Nazareth, T.
    Turner, S. J.
    Raimundo, K.
    Zhou, H.
    Ortiz, B.
    Li, L.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A589 - A589
  • [2] Impact Of Omalizumab On Poor Asthma Control Events And Medication Utilization In Patients With Moderate Or Severe Persistent Asthma
    Yu, T. -C.
    Nazareth, T.
    Turner, S. J.
    Raimundo, K.
    Zhou, H.
    Ortiz, B.
    Li, L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [3] Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting
    Zeiger, Robert S.
    Schatz, Michael
    Dalal, Anand A.
    Qian, Lei
    Chen, Wansu
    Ngor, Eunice W.
    Suruki, Robert Y.
    Kawatkar, Aniket A.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2016, 4 (01): : 120 - +
  • [4] Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
    Szefler, Stanley
    Antonova, Jenya
    Trzaskoma, Benjamin
    Ortiz, Benjamin
    Paknis, Brandee
    Iqbal, Ahmar
    Goldstein, Stanley
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [5] IMPACT OF OMALIZUMAB ON ALL-CAUSE AND ASTHMA-RELATED HEALTH CARE RESOURCE UTILISATION IN PATIENTS WITH MODERATE OR SEVERE PERSISTENT ASTHMA
    Turner, S. J.
    Nazareth, T.
    Raimundo, K.
    Zhou, H.
    Ortiz, B.
    Yu, T. C.
    Li, L.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A599 - A599
  • [6] Lengthening omalizumab dosing interval in treatment of moderate to severe persistent asthma
    Bozoghlanian, Varaz
    Benouni, Saraleen
    Sheinkopf, Lee E.
    Do, Lananh T.
    Katz, Roger M.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB100 - AB100
  • [7] Effect of Omalizumab on measures of control in adolescents with moderate-severe persistent asthma
    Pollard, S. J.
    Maykut, R. J.
    Massanari, M.
    Kianifard, F.
    Zeldin, R. K.
    Geba, G. P.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S10 - S10
  • [8] Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma
    Ohta, Ken
    Miyamoto, Terumasa
    Amagasaki, Taro
    Yamamoto, Manabu
    [J]. RESPIROLOGY, 2009, 14 (08) : 1156 - 1165
  • [9] Reasons for discontinuation of Omalizumab therapy in the treatment of patients with moderate to severe persistent asthma
    Sheinkopf, L. E.
    Rafi, A. W.
    Do, L. T.
    Klaustermeyer, W. B.
    Katz, R. M.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S139 - S139
  • [10] Omalizumab in persistent severe bakers' asthma
    Olivieri, M.
    Biscardo, C. A.
    Turri, S.
    Perbellini, L.
    [J]. ALLERGY, 2008, 63 (06) : 790 - 791
12345